In Brief: Sankyo/Parke-Davis
Executive Summary
Sankyo/Parke-Davis: Sankyo will not share in profits on sales of Warner-Lambert's Accupril through the companies' joint venture, Warner-Lambert says. The Accupril copromotion will take advantage of a 180-rep sales force to be hired by the joint venture. The Sankyo/Parke-Davis venture will promote Accupril and the antidiabetic troglitazone ("The Pink Sheet" Sept. 30, p. 7)...